SCHEMBL9894892

SCHEMBL9894892

Cn1nnc(-c2ccccc2F)c1-c1cn(-c2ccc([N+](=O)[O-])cc2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.43
TDO2 P48775 2/20 0.43
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
CCKBR P32239 1/20 0.38
GABRA3 P34903 1/20 0.38
OPRK1 P41145 1/20 0.38
MC3R P41968 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
GHSR Q92847 1/20 0.38
TLR2 O60603 2/20 0.36
TLR1 Q15399 2/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SCN2A Q99250 1/20 0.35
MAOB P27338 1/20 0.35
DHODH Q02127 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15033463 0.85 TUBB4A (0.36) IDO1TDO2NPC1RAB9ADHODH
SCHEMBL9895968 0.83 ALDH1A1 (0.42) NPC1RAB9AMAOBDHODHALDH1A1
SCHEMBL9897091 0.82 PSEN1 (0.37) NPC1RAB9AMAOBDHODHALDH1A1
SCHEMBL9947564 0.82 MAPT (0.34) NPC1RAB9ADHODHALDH1A1SMN1; SMN2
SCHEMBL2472122 0.77 PTGS1 (0.40) IDO1TDO2GABRA1GABRG2GABRB3
SCHEMBL9895060 0.73 KDM5A (0.36) RAB9ADHODH
SCHEMBL9894887 0.72 PDE2A (0.35) ALDH1A1SMN1; SMN2KDM4E
SCHEMBL9895921 0.72 HTR5A (0.36) NPC1RAB9AGRM5
SCHEMBL21402171 0.71 DHODH (0.37) NPC1RAB9ADHODHALDH1A1SMN1; SMN2
SCHEMBL9894802 0.68 MAPK14 (0.43) GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP claimed
CN-103249728-B Novel triazole compounds III HOFFMANN LA ROCHE 2015-01-21 CN claimed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP claimed
CN-103249728-A Novel triazole compounds III HOFFMANN LA ROCHE 2013-08-14 CN claimed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US claimed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO claimed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US claimed
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
CN-103249728-B Novel triazole compounds III HOFFMANN LA ROCHE 2015-01-21 CN disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
CN-103249728-A Novel triazole compounds III HOFFMANN LA ROCHE 2013-08-14 CN disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 IDO1 1029/4885TDO2 2774/4885GABRA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.